CMBA
DAWN

C.M. Bidwell & Associates’s Day One Biopharmaceuticals DAWN Stock Holding History

C.M. Bidwell & Associates’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-28
Closed -$390 – 500
2024
Q3 		$390 Hold
28
– – ﹤0.01% 481
2024
Q2 		$386 Buy
+28
New +$410 ﹤0.01% 453

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

C.M. Bidwell & Associates's DAWN Position: Q4 2024 in Review

C.M. Bidwell & Associates sold out of Day One Biopharmaceuticals (DAWN) in Q4 2024, closing a stake of 28 shares — an estimated $390 sold.

C.M. Bidwell & Associates first reported a position in DAWN in Q2 2024 and held it in 2 quarters. The position peaked at $390 in Q3 2024. 164 funds tracked by Wall St. Rank hold DAWN as of Q4 2024.

  • C.M. Bidwell & Associates reported no remaining Day One Biopharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 28 Day One Biopharmaceuticals shares in Q4 2024, an estimated $390.
  • C.M. Bidwell & Associates first reported a position in Day One Biopharmaceuticals in Q2 2024 and held it in 2 quarters.
  • C.M. Bidwell & Associates's Day One Biopharmaceuticals position peaked at $390 in Q3 2024.
  • 164 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2024.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2024, filed 12 Feb 2025.